• Something wrong with this record ?

Metabolic Consequences of Advanced Chronic Heart Failure and its Modification by Implantation of a Durable Left Ventricular Assist Device

D. Hlaváček, M. Haluzík, J. Mahrík, G. Popivnyak, BJ. Kasperová, P. Ivák

. 2024 ; 25 (11) : 388. [pub] 20241031

Status not-indexed Language English Country Singapore

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25002221

Heart failure (HF) is a clinical syndrome characterized by the inability of the heart to provide adequate perfusion to tissues and organs, resulting in typical symptoms such as fatigue, dyspnea, dyspepsia, or swelling due to decreased cardiac output. With its increasing prevalence, heart failure has become one of the leading causes of morbidity and mortality worldwide, imposing a significant burden on the population by reducing long-term life expectancy and raising hospital costs. Indeed, over 20 million people worldwide suffer from heart failure, with a 5-year mortality rate of 60-70%. As heart failure progresses, various structural and metabolic changes occur within the myocardium and organ systems. In the past two decades, therapeutic options for heart failure patients have significantly expanded. In addition to novel pharmacological treatment, advanced surgical methods such as heart transplantation (HTx) and the implantation of durable left ventricular assist devices (LVADs) are available for patients with end-stage heart failure. This review discusses the pathophysiological aspects and metabolic consequences of heart failure and metabolic changes, as well as the benefits and challenges of implanting a left ventricular assist device. Furthermore, future targets for heart failure diagnostics and therapy will be highlighted.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002221
003      
CZ-PrNML
005      
20250123102016.0
007      
ta
008      
250117s2024 si f 000 0|eng||
009      
AR
024    7_
$a 10.31083/j.rcm2511388 $2 doi
035    __
$a (PubMed)39618874
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a si
100    1_
$a Hlaváček, Daniel $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Department of Physiology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $1 https://orcid.org/0000000184531666
245    10
$a Metabolic Consequences of Advanced Chronic Heart Failure and its Modification by Implantation of a Durable Left Ventricular Assist Device / $c D. Hlaváček, M. Haluzík, J. Mahrík, G. Popivnyak, BJ. Kasperová, P. Ivák
520    9_
$a Heart failure (HF) is a clinical syndrome characterized by the inability of the heart to provide adequate perfusion to tissues and organs, resulting in typical symptoms such as fatigue, dyspnea, dyspepsia, or swelling due to decreased cardiac output. With its increasing prevalence, heart failure has become one of the leading causes of morbidity and mortality worldwide, imposing a significant burden on the population by reducing long-term life expectancy and raising hospital costs. Indeed, over 20 million people worldwide suffer from heart failure, with a 5-year mortality rate of 60-70%. As heart failure progresses, various structural and metabolic changes occur within the myocardium and organ systems. In the past two decades, therapeutic options for heart failure patients have significantly expanded. In addition to novel pharmacological treatment, advanced surgical methods such as heart transplantation (HTx) and the implantation of durable left ventricular assist devices (LVADs) are available for patients with end-stage heart failure. This review discusses the pathophysiological aspects and metabolic consequences of heart failure and metabolic changes, as well as the benefits and challenges of implanting a left ventricular assist device. Furthermore, future targets for heart failure diagnostics and therapy will be highlighted.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Haluzík, Martin $u Department of Diabetes, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University, 128 08 Prague, Czech Republic
700    1_
$a Mahrík, Jakub $u Department of Anesthesia and Resuscitation, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Charles University in Prague, 121 08 Prague, Czech Republic
700    1_
$a Popivnyak, Ganna $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Charles University in Prague, 121 08 Prague, Czech Republic
700    1_
$a Kasperová, Barbora J $u Department of Diabetes, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Charles University in Prague, 121 08 Prague, Czech Republic
700    1_
$a Ivák, Peter $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Department of Physiology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $u Second Department of Surgery, Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic
773    0_
$w MED00203331 $t Reviews in cardiovascular medicine $x 2153-8174 $g Roč. 25, č. 11 (2024), s. 388
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39618874 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123102010 $b ABA008
999    __
$a ok $b bmc $g 2254506 $s 1238224
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 25 $c 11 $d 388 $e 20241031 $i 2153-8174 $m Reviews in cardiovascular medicine $n Rev Cardiovasc Med $x MED00203331
LZP    __
$a Pubmed-20250117

Find record

Citation metrics

Archiving options